ArticleAvicenna journal of phytomedicine2026
Comparing the effects of saffron and Mucosamin® spray on oral mucositis induced by radiotherapy: A randomized controlled clinical trial.
Article in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Mucositis is a common oral complication of the non-surgical therapy of cancer. Numerous studies have explored the pharmacological effects of saffron (Crocus sativus) in medicine. This study aimed to compare the effectiveness of saffron extract to Mucosamin® on relieving radiotherapy-induced oral mucositis. Materials and Methods: This randomized controlled clinical trial was conducted on head and neck cancer patients who received radiotherapy treatment at the oncology clinic of Shahid Beheshti Hospital in Qom. A total of 68 patients were divided into two groups of 34. In addition to standard treatment, the first group received six puffs of brewed saffron spray (100 mg) daily, and the second group received six puffs of Mucosamin® for 4 weeks. Repeated measures ANOVA, T-test, and Chi-square test were utilized to analyze pain intensity and mucositis grading. All data were analyzed using SPSS version 22. Results: The average pain intensity and mucositis grade decreased in both groups (a total of 61 patients). At baseline, the average pain intensity for the saffron and Mucosamin® groups was 6.29 ± 1.61 and 6.70 ± 1.93. By the end of the study, these figures dropped to 3.61 ± 1.35 and 4.00 ± 1.23. Likewise, the average mucositis grade in the two groups was 2.87 ± 0.34 and 2.56 ± 0.50 at the baseline, decreasing to 2.70 ± 0.46 and 2.40 ± 0.49 at the end of the study, respectively. There was no significant difference in the reduction of mucositis grade (p = 0.246) or pain intensity (p = 0.38) between the two groups. Conclusion: The brewed saffron spray showed effectiveness comparable to Mucosamin® spray in reducing pain intensity and grading oral mucositis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.